Note: Ingredients listed on restricted chemical lists
EC/CAS
9004-64-2
Name of the chemical
hydroxypropylcellulose
Concentration
N/A
EC/CAS
9005-65-6
Name of the chemical
polyethyleneglycol sorbitan monooleate
Concentration
N/A
EC/CAS
207-439-9
Name of the chemical
Calcium carbonate
Concentration
N/A
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
N/A
General Information
Revision date
2013-02-06
Product name
Lipitor
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
Section 2
SECTION 2: Hazards identification
Appearance: White film-coated tablets
Hazard statements
Non-hazardous in accordance with international standards for workplace safety.
Additional information
Short Term: May cause eye irritation (based on components) . Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. Known Clinical Effects: Adverse effects associated with therapeutic use of atorvastatin include constipation, flatulence, upset stomach, and abdominal pain. Clinical use of this drug has caused changes in liver function, muscle pain, weakness. EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
